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Abstract
Medications that can mitigate against radiation injury are limited. In this study, we investigated the ability of recombinant
human growth hormone (rhGH) to mitigate against radiation injury in mice and nonhuman primates. BALB/c mice were
irradiated with 7.5 Gy and treated post-irradiation with rhGH intravenously at a once daily dose of 20 mg/dose for 35 days.
rhGH protected 17 out of 28 mice (60.7%) from lethal irradiation while only 3 out of 28 mice (10.7%) survived in the saline
control group. A shorter course of 5 days of rhGH post-irradiation produced similar results. Compared with the saline control
group, treatment with rhGH on irradiated BALB/c mice significantly accelerated overall hematopoietic recovery. Specifically,
the recovery of total white cells, CD4 and CD8 T cell subsets, B cells, NK cells and especially platelets post radiation exposure
were significantly accelerated in the rhGH-treated mice. Moreover, treatment with rhGH increased the frequency of
hematopoietic stem/progenitor cells as measured by flow cytometry and colony forming unit assays in bone marrow
harvested at day 14 after irradiation, suggesting the effects of rhGH are at the hematopoietic stem/progenitor level. rhGH
mediated the hematopoietic effects primarily through their niches. Similar data with rhGH were also observed following
2 Gy sublethal irradiation of nonhuman primates. Our data demonstrate that rhGH promotes hematopoietic engraftment
and immune recovery post the exposure of ionizing radiation and mitigates against the mortality from lethal irradiation
even when administered after exposure.
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Introduction
The misuse of ionizing radiation or nuclear devices as weapons
of terrorism has been recognized as a major public health threat
[1,2]. In the event of a nuclear detonation, terrorist radiological
(e.g., ‘‘dirty’’) bomb, or attack on a nuclear power plant, casualties
may be generated well outside the periphery of the lethal zone.
Depending on the type of nuclear device, these casualties may
range from trivial biological exposures (nonetheless causing severe
anxiety) to acute high-dose exposures that result in the
development of severe radiation sickness and death. Typically,
individuals exposed to ionizing radiation doses in the range of 0.7
to 4 Gy will develop symptoms that are secondary to hematopoi-
etic and immune damage [3]. At exposures approximating 4 Gy, it
is estimated that 50% of individuals will die within 60 days unless
there is medical intervention [1,3]. The majority of deaths that
occur from exposures of 4–10 Gy also result, in a large part, from
the sequelae of hematopoietic and immune failure (bleeding and
infections). In addition, even at levels of radiation exposure
significantly lower than those needed to cause symptoms of
radiation sickness, there are alterations of the immune system so
that the virulence and infectivity of biological agents (bacteria,
viruses and fungi) are dramatically increased [4,5]. A compro-
mised immune system exacerbates the effects of infectious agents,
including other biological pathogens such as anthrax, and may
preclude the use of vaccines. Unfortunately, therapeutic agents
capable of promoting or accelerating the recovery of the
hematopoietic and/or immune compartments following radiation
injury are limited [1,2,3].
The potential relationship between the neuroendocrine system
and hematopoiesis has been postulated for many years [6].
Growth hormone, which is produced by the anterior pituitary, has
been demonstrated to have a stimulatory role in erythropoiesis
[7,8] and granulopoiesis [9] either through direct effects or
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11056indirectly via the action of insulin-like growth factor 1 (IGF-1)
[7,8]. Growth hormone also stimulates lymphocyte production in
rodents and growth hormone replacement in hypophysectomized
animals has been associated with recovery of thymic function
[10,11]. These biologic features, along with its demonstrated safety
profile of recombinant human growth hormone (rhGH) in
humans, make rhGH an attractive candidate for use in the
treatment of victims of ionizing radiation exposure where one’s
hematopoietic and immune systems can be rapidly and severely
depleted.
In this study, we investigated the utility of rhGH following lethal
and sub-lethal irradiation and its effect on the reconstitution of
hematologic and immune systems using both mouse and
nonhuman primate models. The results indicate that rhGH
enhances both hematologic engraftment and immune recovery
and mitigates the mortality from lethal and non-lethal irradiation.
These beneficial effects are a result of enhanced hematopoiesis
after treatment with rhGH. rhGH augments hematopoiesis mainly
through impacting hematopoietic niches.
Results
rhGH mitigates against lethal irradiation
We first tested the ability of rhGH to mitigate against lethal
irradiation in mice. BALB/c mice were whole-body irradiated
with 7.5 Gy and treated with rhGH intravenously once daily at a
dose of 20 mg/dose/day for 35 days starting within one hour post
radiation exposure. As shown in Fig. 1A, 60.7% of the mice
treated with rhGH survived more than 100 days post radiation
exposure while only 10.7% of the mice in the control group
survived, demonstrating that rhGH possesses significant radiopro-
tective effect. This effect was still detectable when the radiation
dose was increased to 8.5 Gy although all the animals ultimately
died (Fig. 1B). To further characterize the radioprotective effects of
Figure 1. rhGH mitigates against lethal irradiation. BALB/c mice were irradiated with 7.5 Gy (all except B) or 8.5 Gy (B) and treated with rhGH
i.v. daily at a dose of 20 mg/dose/day for 5 or 35 days. Unless where indicated, rhGH was given within one hour post irradiation. Survival was
monitored daily. The bars represent the period of the time that the animals were treated. The data were from the combined results from 2–3
experiments. Each experiment had similar design (n=8–10 animals per group) and results. (A) Treated for 35 days; (B) 8.5 Gy irradiation and treated
daily until death; (C) Treated for 5 days and time of the first dose. P,0.05, 1 hr vs. other groups. rhGH stands for recombinant human growth
hormone.
doi:10.1371/journal.pone.0011056.g001
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frequently. When we shortened the treatment time from 35 days to
5 days, the radioprotective effect was still significant (Fig. 1C, 100-
day survival: 60% vs. 20%).
Because victims may not be able to receive medical treatment
until several hours to days following radiation exposure, it would
be useful to determine how long we can wait before the
administration of the first dose of rhGH. Administration of the
first dose of rhGH after 6 and 12 hours demonstrated a trend to
improved survival but did not achieve statistical significance
(Fig. 1C).
The mice used for the above experiments were 8–12 weeks old
BALB/c mice. To ascertain that the effects of rhGH were not
strain specific, we repeated the experiment with C57BL/6 mice.
C57BL/6 mice were irradiated with 9 Gy and treated with rhGH
(20 mg/dose/day, i.v.) once a day for 5 days starting within one
hour post radiation exposure. As demonstrated in Fig. S1, similar
to the data obtained from BALB/c mice, rhGH was also able to
mitigate against lethal irradiation in C57BL/6 mice.
It is important to point out that all the irradiated mice survived
more than 100 days remained healthy for more than one year. All
animals appeared to be normal. When tested more than one year
post irradiation, the hematologic and immune parameters
remained within the normal range and no tumors were found in
all survivors at autopsies.
rhGH facilitates hematologic recovery post radiation
exposure
Hematopoietic cells are amongst the most sensitive cell types to
ionizing radiation and the mice often die from the sequelae of
hematopoietic and immune failure (bleeding and infections) [1,3].
To understand how rhGH mitigates against lethal irradiation, we
monitored the recovery of white cells and platelets in peripheral
blood following irradiation with 7.5 Gy. As demonstrated in
Fig. 2A, treatment with rhGH significantly accelerated the
recovery of total white blood cells. The difference in white counts
was first detected at day +21 and lasted until day +56. The white
cell counts in both groups recovered back to normal or near
normal at day +70 and completely normal by day +100. Similar
results were observed with platelets (Fig. 2B). Platelet counts in the
rhGH-treated group recovered back to normal by day +56 while
the platelet counts in the saline control group did not recover to
normal levels until day +100.
rhGH enhances immune recovery post radiation
exposure
Infections are one of the most frequent consequences following
significant radiation exposure and are caused by the weakened
immune system [3,5]. Since rhGH has previously been demon-
strated by our group and others to be able to facilitate immune
recovery post hematopoietic stem cells transplantation and
immunosuppressive therapy [10,11,12], we sought to determine
whether rhGH can elicit the same effect post radiation exposure on
the residual host cells. Thus, we monitored the kinetics of T, B, and
NK cell recovery in peripheral blood in the irradiated (7.5 Gy) mice
treated with rhGH. As demonstrated in Fig. 3, rhGH facilitated the
recovery of CD4
+ T cells and B cells (B220
+CD3
2CD49b
2). Even
though there were clear treads toward the increase of CD8+ T cell
and NK cell (CD3
2CD49b
+) counts in the rhGH-treated mice
compared with the control mice, the differences were not
statistically different as analyzed by repeated measures analysis of
varience (ANOVA). When analyzed by Student’s t-test, significant
differences were observed in multiple time points in both CD8
+ T
cell and NK cell (CD3
2CD49b
+) counts as indicated in Fig. 3.
CD4
+ T cell, CD8
+ T cell, and B cell counts in rhGH-treated mice
recovered back to normal or near normal by day +100. By contract,
all lymphocyte counts were only half or less than half of the normal
levels in the saline control group at day +100.
rhGH promotes the recovery of hematopoietic stem/
progenitor cells post radiation exposure
Growth hormone has been demonstrated to have a stimulatory
role in erythropoiesis [7,8] and granulopoiesis [9]. We have also
demonstrated that the number of hematopoietic stem/progenitor
cells positively correlates with the speed of hematological and
immune recovery [13]. Based on these previously published data,
Figure 2. rhGH facilitates hematological recovery post irradiation. BALB/c mice were irradiated with 7.5 Gy and treated with rhGH for 35
days. White counts were determined by flow cytometer using CD45 antibody. Platelet counts were determined by hemacytometer. The dash line
represents the pre-irradiation level. Each group contained 10 animals. (A) White cells; (B) Platelets.
*P,0.05, rhGH vs. saline control as analyzed by
Student’s t-test; P,0.01, rhGH vs. saline control as analyzed by repeated measures ANOVA. rhGH stands for recombinant human growth hormone.
doi:10.1371/journal.pone.0011056.g002
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recovery following irradiation by promoting hematopoiesis. To
test this hypothesis, we measured the recovery of hematopoietic
stem/progenitor cells post irradiation by flow cytometry and
colony forming unit assays. BALB/c mice were irradiated (7.5 Gy)
and treated with rhGH daily starting within one hour post
irradiation. At day +14, all mice were sacrificed and the bone
marrow was harvested in order to quantify the number of
hematopoietic stem and progenitor cells. We first measured the
content of hematopoietic progenitor cells by colony forming unit
assays. As demonstrated in Table 1, the bone marrow from the
rhGH-treated mice had significant higher numbers of CFU-GM
and BFU-E and CFU-GEMM compared with the saline control
mice did. The numbers of BFU-E and CFU-GEMM were even
higher than the normal level (Table 1). Interestingly, the number
of nucleated cells per colony was also significantly higher in the
rhGH-treated group than that in the saline control group,
suggesting that the ability of progenitors to generate the progenies
is also enhanced after rhGH treatment. Consistent with the data
from the colony forming unit assays, the frequency of c-Kit
+Sca-
1
+Lin
2 (KSL) cells, which are highly enriched for both long and
short term stem cells, was higher in the rhGH-treated group than
that in the saline control group. Further testing of long term
hematopoietic stem cells (CD150
+CD48
2CD244
2) [14] in bone
marrow demonstrated that the frequency of these cells was also
increased in rhGH-treated mice compared with that in the saline
control mice. Histological analyses at day 14 post irradiation
(Fig. 4) demonstrated that the treatment with rhGH significantly
increased the cellularity in bone marrow as compared with the
saline control, further confirming that rhGH enhances hemato-
poietic recovery post radiation exposure.
Effects of rhGH on apoptotic and mitotic death of
hematopoietic stem/progenitor cells post radiation
exposure
Cells die either through apoptosis or mitotic death following
irradiation. In order to determine how rhGH protects hemato-
poietic stem/progenitor cells post radiation exposure, we irradi-
Figure 3. rhGH enhances immune recovery post irradiation. BALB/c mice were irradiated with 7.5 Gy and treated with rhGH for 35 days.
Phenotypic immune recovery was monitored in peripheral blood by flow cytometry. The dash line represents the pre-irradiation level. Each group
contained 10 animals. (A) CD4
+ T cells; (B) CD8
+ T cells; (C) B cells; (D) NK cells. *P,0.05, rhGH vs. saline control as analyzed by Student’s t-test; P,0.01,
rhGH vs. saline control for CD4+ and B cells as analyzed by repeated measures ANOVA. rhGH stands for recombinant human growth hormone.
doi:10.1371/journal.pone.0011056.g003
Radioprotection by rhGH
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11056ated purified KLS cells from C57BL/6 bone marrow at 4 Gy and
cultured them with 5 nM of rhGH (this concentration was chosen
based on the published data [7,8,9] and our preliminary testing) in
the presence of thrombopoietin, stem cell factor, and Flt3 ligand.
The percentages of apoptotic and dead cells were then determined
by flow cytometry after stained with 7-AAD and annexin V at
various time points post radiation exposure. As demonstrated in
Fig. 5A, rhGH did not protect hematopoietic stem/progenitor
cells from undergoing apoptosis when measured 24 hours post
treatment. No significant effects on cell death were observed after
treatment with rhGH when measured at 24 hours post radiation
exposure (Fig. 5B). Similar data were observed when measured at
48 and 72 hours post irradiation (data not shown).
In vitro effect of rhGH on irradiated hematopoietic stem
and progenitor cells
In order to further understand how rhGH promoted hemato-
poietic recovery post irradiation, we studied the effect of rhGH on
irradiated hematopoietic stem and progenitor cells using in vitro
assays. Purified KSL cells from C57BL/6 bone marrow were
irradiated with 3 Gy and cultured with 5 nM of rhGH in the
presence of thrombopoietin, stem cell factor, and Flt3 ligand
(TSF). After 7 days in culture, the cells were harvested and the
numbers of CFCs and CFU-S were determined. As demonstrated
in Fig. 5C, rhGH did not seem to have an effect on the number of
CFCs, which measures the frequency of hematopoietic progenitor
cells. Surprisingly, rhGH seemed to decrease the number of day
11 CFU-S (Fig. 5D), which is a measurement for long-term
hematopoietic stem cell content. These data suggest that rhGH
has limited direct effects on irradiated hematopoietic progenitor
cells and has negative direct effects on irradiated long-term
hematopoietic stem cells.
To determine whether rhGH can augment hematopoiesis
indirectly through other cell types, we added osteoblasts in the
cultures. Osteoblasts have been recently demonstrated to be a
critical component of the hematopoietic stem cell niche
[15,16,17]. The results in Fig. 5C, D demonstrated that osteoblasts
independently increased CFCs but not the number of day
11 CFU-S. In the presence of osteoblasts, rhGH significantly
increased the number of CFU-S and trended to increase CFCs
compared with TSF alone. All the effects of osteoblast are
mediated by soluble factors because the osteoblasts had no direct
contact with hematopoietic stem/progenitor cells. These data
indicate that rhGH may augment hematopoietic stem/progenitor
cell activity through osteoblasts.
rhGH increases the plasma level of IGF-1
It was previously demonstrated that growth hormone mediates
at least some of its effects on hematopoiesis through production of
IGF-1 [9]. To investigate whether it is the case in our model, we
measured the plasma level of IGF-1 at day +14 post irradiation.
IGF-1 levels were decreased in all irradiated mice compared with
normal BALB/c mice (Fig. 6). After treated with rhGH, IGF-1
levels were significantly increased compared with the saline control
group, demonstrating that the treatment with rhGH does increase
the blood level of IGF-1.
Table 1. Effect of rhGH on hematopoiesis.
Groups CD150
+ CD48
2 CD244
2 KSL cells CFU-GM BFU-E CFU-GEMM Cells (610
4) per colony
(/10
5 bone marrow cells)
Normal BALB/c ND 80.1624.3 45.466.3 8.460.9 4.961.2 7.160.6
Saline control 0.660.6 11.865.1 14.362.4 6.162.3 2.660.5 4.561.3
rhGH 4.162.6
a 29.3616.8
a,b 36.8610.6
a 11.262.2
a,b 7.661.8
a,b 7.760.7
a
BALB/c mice were irradiated with 7.5 Gy and treated with rhGH for 5 days. Mice were sacrificed and bone marrow was harvested at day +14 post irradiation. Frequencies
of CD150
+CD48
2CD244
2 and KSL cells were determined by flow cytometry. CFUs were determined after 12 days in culture. Each group contains 4–10 animals. This is a
representative of three similar experiments. rhGH stands for recombinant human growth hormone; KSL cells, cells expressing c-Kit
+Sca-1
+Linage
2/low phenotype; CFU-
GM, colony forming unit-granulocyte & monocyte; BFU-E, burst forming unit-erythrocyte; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, monocyte, and
megakaryocyte.
aP,0.05, saline control vs. rhGH;
bP,0.05,. rhGH vs. normal BALB/c.
doi:10.1371/journal.pone.0011056.t001
Figure 4. Histological analyses. BALB/c mice were irradiated with 7.5 Gy and treated with rhGH i.v. daily at a dose of 20 mg/dose/day. Mice were
sacrificed on day +14 and tibia was stained with hematoxylin and eosin and analyzed. The magnification was 12.66. (A) Normal BALB/c mice; (B)
Saline control; (C) rhGH. rhGH stands for recombinant human growth hormone.
doi:10.1371/journal.pone.0011056.g004
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post sublethal irradiation in nonhuman primates
The data presented above convincingly demonstrate that rhGH
enhances both hematologic and immune recovery post radiation
exposure in mice. Since similar clinical studies can not be ethically
conducted in humans, demonstration of similar results in a second
different species other than rodents would be needed before it can
be used as a medical countermeasure for radiation injury in
humans [18]. Because of the high degree of genetic and
physiologic similarity of nonhuman primates to human beings
[19,20], cynomolgus monkeys were chosen as a second animal
model to test the efficacy of rhGH. Cynomolgus monkeys were
irradiated with 2 Gy whole-body and treated with rhGH at a once
daily dose of 5 mg/kg for 30 days. The control animals were
irradiated and injected with saline. Peripheral blood cell counts
were assayed daily for the first 5 days, then 3 times weekly for the
remainder of a 30-day period the first month, every other week in
the second month, and once a month thereafter. As shown in
Fig. 7, time trend analyses of the data using a regression model
Figure5. InvitroeffecsofrhGH on hematopoieticstem/progenitor cells.Irradiated (3 Gy [C,D]or 4 Gy [A,B])c-Kit+Lin-Sca-1+ cells from C57BL/
6 mice were cultured with thrombopoietin, stem cell factor, Fl3 ligand and various concentration of recombinant human growth hormone. In some
experimentsshowninCandD,osteoblastswereaddedtotheculture.After24 hoursinculture,percentagesofapoptotic (A)anddead(B)cellsamongc-
Kit
+Lin
2Sca-1
+ hematopoietic stem/progenitor cells were determined by flow cytometry. Similar results were obtained at 48 and 72 hours. In the
experiments shown in C and D, the cells were harvested after 7 days in culture. The frequencies of hematopoietic stem and progenitor cells were then
determined by in vitro colony forming unit assay (C) and in vivo CFU-S assay (D) respectively.
*P,0.05,
**P,0.01,
***P,0.001. rhGH stands for
recombinant human growth hormone; TSF, thrombopoietin, stem cell factor, Fl3 ligand, CFU-S, colony forming unit-spleen; CFC, colony forming cell.
doi:10.1371/journal.pone.0011056.g005
Figure 6. rhGH increases the plasma level of IGF-1. BALB/c mice
were irradiated with 7.5 Gy and treated with rhGH for 5 days. Plasma
IGF-1 levels were determined by ELISA.
*P,0.0001, saline control vs.
other groups;
&P=0.01, rhGH vs. normal BALB/c. rhGH stands for
recombinant human growth hormone; IGF-1, insulin-like growth factor.
doi:10.1371/journal.pone.0011056.g006
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blood cells (P,0.05), monocytes (P,0.01), and eosinophils
(P,0.05) and trended to a faster recovery of neutrophils and
lymphocytes compared with saline control. Even though there
were clear treads toward increased neutrophils and lymphocytes in
the rhGH treated cynomolgus monkeys (Fig. 7), the differences
were not significant, probably due to small sample sizes.
Nevertheless, further analyses using Student’s t-test demonstrated
statistical differences between rhGH- treated and saline control
groups in total white blood cells (717061600 vs. 501061450,
P=0.01), lymphocytes (24406650 vs. 17906650, P,0.05), and
eosinophils (4906330 vs. 2006150, P,0.05) at week +9 and total
white blood cells (994062200 vs. 61006590, P=0.01), neutro-
phils (618062220vs. 308061170, P,0.05), and monocytes
(6006200 vs. 310660, P,0.05) at week +18. Taken together,
significant increased numbers of total white blood cells and all
major white cell subsets were demonstrated in rhGH treated
nonhuman primates after sublethal irradiation. No effects of rhGH
on red blood cell, hematocrit, hemaglobin, and platelet recovery
were detected (data not shown). The differences in all cell counts
resolved after 22 weeks post irradiation. Similar to the mouse data,
these data demonstrate that rhGH is able to enhance the recovery
of total white cells, neutrophils, lymphocytes, monocytes, and
eosinophils post sublethal radiation injury in nonhuman primates,
suggesting the recovery of both innate and adaptive immunity are
enhanced after rhGH treatment.
Discussion
Previously published data have demonstrated that rhGH
enhances hematologic engraftment and immune recovery post
hematopoietic stem cell transplantation [12,21]. In this report, we
have further demonstrated that rhGH also has significant
radioprotective effects against lethal irradiation in two different
strains of mice when administrated post radiation exposure. This
effect is a result from the positive effects of rhGH on hematopoietic
recovery. In addition, rhGH enhances immune reconstitution post
radiation exposure. We have further confirmed the beneficial
effects of rhGH in post-irradiation white cell recovery using a
nonhuman primate model.
Different cells and tissues have different sensitivities to ionizing
radiation [2,22]. Hematopoietic cells are among the cell types that
are most sensitive to radiation[2]. In fact, the majority of deaths
that occur from exposures of 4–10 Gy result, in a large part, from
the sequelae of hematopoietic and immune failure (bleeding and
infections) [3]. Even though a number of agents such as thiol
compounds [23,24],interleukin (IL)-1 [23,24,25], tumor necrosis
factor a [25,26], stem cell factor [26,27], IL-12 [28], basic
fibroblast growth factor [29], flt3 ligand [30,31], CBLB502 [32],
granulocyte colony stimulating factor (G-CSF) [23,33,34], gran-
ulocyte & macrophage colony stimulating factor (GM-CSF) [35],
and combinations of cytokines and growth factors [36] have been
shown to be able to protect against lethal irradiation, only a few of
Figure 7. rhGH accelerates white blood cell recovery post sublethal irradiation in nonhuman primates. After irradiated with sublethal
whole body irradiation (2 Gy), cynomolgus monkeys were treated with rhGH at a once daily dose of 5 mg/kg for 30 days. Peripheral blood counts
were measured overtime. The data were combined from two similar experiments. There were 8 animals (n=4 for both study #1&#2) in the saline
control group and 11 animals (n=6 in study #1, n=5 in study #2) in the rhGH-treated group. The data were analyzed by using a regression model.
Data from individual animals (dash line) as well as fitted lines (solid lines) were shown. (A) Total white blood cells. P,0.05. (B) Neutrophils. (C)
Lymphocytes. (D) Monocytes. P,0.01. (E) Eosinophils. P,0.05.
doi:10.1371/journal.pone.0011056.g007
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are effective when administered post radiation exposure. None of
them have been approved by the Food and Drug Administration
for the management of radiation-induced marrow aplasia so far.
We chose to study rHGH as a radiation mitigator because it is an
approved drug, available in the market and thus may be easier to
be developed as a medical countermeasure for radiation injury in
humans. In addition, rhGH can also be used in combination with
G-CSF or GM-CSF because rhGH can also facilitate immune
recovery (Fig. 4) while G-CSF [37] and GM-CSF [38] can not.
Even though both G-CSF and rhGH are effective in protection
against lethal radiation, the window of radiation doses for which
they have an effect is narrow. Treatment with rhGH leads to long
term survival of more than 60% of the BALB/c mice irradiated
with 7.5 Gy (Fig. 1A) while all the BALB/c mice irradiated with
8.5 Gy survive longer after treatment with rhGH, but die within
30 days (Fig. 1B). Similarly, G-CSF is able to rescue about half of
the BDF1 mice irradiated with 9.5 Gy [33] but G-CSF is not
effective anymore after the radiation dose is increased to 10.5 Gy
[33]. These observations suggest that, similar to G-CSF, the use of
rhGH will be restricted to a narrow window of radiation doses
when used as a sole agent to mitigate lethal irradiation and that the
effects are primarily on the hematopoietic system. While the mice
were kept in a specific pathogen free facility during the studies,
mortality could be a result of infections. Yet we could not detect
bacteria in blood cultures performed on moribund mice at various
timepoints post irradiation (data not shown), suggesting that death
from infections was unlikely. Another target organ of irradiation
for acute mortality at the dose of 7.5 Gy could be intestine [22].
However, the level of citruline, a reliable indicator of small
intestine injury [39], recovered back to normal quickly in both
control and treated groups (Table S1), suggesting that gut injury is
not a primary cause of death at this dose of radiation. Another
issue is how long we can delay the treatment after irradiation. This
practical aspect is important because radiation victims may not be
able to receive treatment until hours or days post exposure. For
example, G-CSF is not very effective when given 24 hours post
exposure [34]. Similarly, the effect of rhGH is decreased when the
first dose is delayed until 6 and 12 hours post irradiation (Fig. 1C).
These observations indicate that the radiation victims need to be
treated as soon as possible after exposure at least for the acute
effects of rhGH on hematopoiesis. It is of note that rhGH could be
used later for its effects on the immune system [40].
At the radiation dose of 7.5 Gy, death is usually caused by
hematological failure [3]. Indeed, both white cell andplatelet counts
drop to a very low level (Fig. 2) and the bone marrow was essentially
empty (Fig. 4). Treatment with rhGH significantly accelerates the
recovery of both white cell and platelet counts (Fig. 2), suggesting
that the effects of rhGH may be at the hematopoietic stem/
progenitor level. Histological analysis (Fig. 4) supports this notion as
the cellularity in the bone marrow of rhGH-treated mice is
dramatically increased comparing with that in the saline control
mice. Measurement of CFCs in the bone marrow at day +14
(Table 1) conclusively demonstrate the contents of all lineages of
hematopoietic progenitor cells are increased after rhGH treatment.
Increase frequencies of bone marrow KSL cells as well as more
primitiveCD150
+CD48
2CD244
2cells[14] (Table 1)indicatesthat
rhGH works at the stem cell level. rhGH also increases the
proliferative activity of hematopoietic progenitor cells because the
cells per colony are statistically increased in the mice treated with
rhGH (Table 1). These observations suggest that rhGH not only
promotes the recovery of hematopoietic stem and progenitor cells
but also enhances the ability of progenitor cells to generate their
progenies. Both pathways should contribute to the accelerated
recovery of peripheral blood counts post rhGH treatment, which is
crucial for the survival of radiation victims.
How does rhGH promote hematopoietic stem/progenitor
recovery post irradiation? Ionizing radiation damages DNA and
causes both apoptotic and mitotic death [22]. rhGH could protect
hematopoietic stem/progenitor cells from apoptosis and mitotic
death [41]. However, our data shown in Fig. 5A, B indicate that
rhGH does not protect against either apoptosis or death of
irradiated hematopoietic stem/progenitor cells. Because some of
the hematopoietic stem and progenitor cells do survive even after
lethal dose of irradiation [42], another possibility is that rhGH
promotes the expansion of the surviving hematopoietic stem/
progenitor cells directly or indirectly. But our in vitro data
presented in Fig. 5C, D suggest that rhGH has limited direct
effects on hemapoietic stem/progenitor cells. It is most likely that
rhGH promotes the expansion of the surviving hematopoietic stem
and progenitor cells indirectly through other cell types such as
osteoblast in the hematopoietic niches as suggested by the data
presented in Fig. 5C, D. Osteoblasts have recently been
recognized as an important component of hematopoietic stem
cell niche [15,16,17]. rhGH activates osteoblasts after binding to
the growth hormone receptor expressed on osteoblasts [43]. Upon
activation, osteoblasts can produce several necessary soluble and
membrane-associated factors capable of regulating hematopoietic
stem/progenitor cells [44,45]. Indeed, rhGH is able to expand
hematopoietic stem and progenitor cells only when osteoblasts are
present (Fig. 5C, D), demonstrating that rhGH can promote
irradiated hematopoietic stem/progenitor cell activity through its
effects on osteoblasts. These data are consistent with the previously
published data indicating rhGH requires stromal cells to stimulate
erythropoiesis and granulopoiesis [7,8,9,46,47]. The fact that
direct contact between osteoblasts and hematopoietic stem/
progenitor cells is not required for rhGH’s effects (Fig. 5C, D)
suggests that the stimulating effects are mediated by soluble
factor(s). It has been previously demonstrated that osteoblasts can
produce several hematopoietic cytokines including G-CSF, GM-
CSF, IL-6, leukemia inhibitory factor, and stromal-derived factor
1 [44,45]. It is currently not clear whether rhGH can promote
osteoblasts to secrete these hematopoietic cytokines. Because
rhGH is able to induce bone formation [48], another pathway that
rhGH uses to promote hematopoiesis is through increasing the
number of osteoblasts. However, trabecular bone fraction (% BV/
TV) as determined by quantitative microCT in tibias harvested at
14 days post irradiation is similar between the rhGH-treated and
saline control groups (data not shown), suggesting that an increase
of trabecular bone formation may not be responsible for the
enhanced hemapoiesis after treatment with rhGH.
It was previously demonstrated that rhGH mediates at least
some of its effects on hematopoiesis through production of IGF-1
[9]. In our model, treatment with rhGH significantly increases
systemic level of IGF-1 (Fig. 6). Because it is known that IGF-1 can
promotes hematopoiesis [49], the increased plasma level of IGF-1
likely leads to enhanced hematopoietic recovery. Indeed, it has
been demonstrated that IGF-1 decreases apoptosis and promotes
survival of hematopoietic progenitors in a PI3-kinase-dependent
manner [50,51]. IGF-1 activates the serine/threonine kinase Akt
through PI3-kinase. This activation phosphorylates and inhibits
caspase 3 resulting in decreased apoptosis [52].
We have previously demonstrated that the number of
hematopoietic stem/progenitor cells directly correlates with the
speed of immune reconstitution [13]. Since the number of
hematopoietic stem cells is increased in the rhGH-treated mice
(Table 1), it was expected that immune recovery is also accelerated
in these animals as demonstrated in Fig. 3. rhGH can also
Radioprotection by rhGH
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11056stimulate the expansion of mature immune cells directly [41]. The
fact that only the numbers of white cell and its subsets are increased
but not those of red blood cells and platelets after treatment with
rhGH in sublethal irradiated nonhuman primates (Fig. 7) does
suggest this could be the case. Nevertheless, the positive effects of
rhGH on immune recovery make rhGH a very attractive candidate
for a medical countermeasure against radiation injury because
infections are one of major causes of death [4,5]. In fact, it was
recently reported that rhGH is able to enhance thymopoiesis in
HIV/AIDS patients [53]. A clinical trial has also been initiated in
our group to test the efficacy of rhGH toward enhancing immune
reconstitution post cord blood transplantation.
There are several theoretical concerns with the use of rhGH [6].
One of the concerns is whether rhGH promotes the autoimmune
phenomena because rhGH potentiates the proliferation and
cytokine responses of T cells in response to antigens. Another
concern is whether rhGH promotes the growth of cancers. In order
to address these concerns, we monitored the surviving mice treated
with rhGH for more than one year post irradiation. All the animals
appeared to be normal throughout the study. Both the body weights
and hematological and immune parameters in the long term
survivors were normal. No tumors were detected in any long term
survivors. These observations suggest that rhGH is unlikely to
promote autoimmunity and the growth of cancer in the radiation
victims. Moreover, the clinical monitoring in normal individuals
with short stature receiving rhGH has not demonstrated an
increased risk of malignancies or autoimmune diseases [54].
In conclusion, rhGH promotes hematopoietic and immune
recovery post radiation exposure and protects against lethal and
sub-lethal irradiation when administered after irradiation. rhGH is
an attractive candidate for mitigation of toxicity from irradiation
and should be tested further as a medical countermeasure against
radiation injury.
Materials and Methods
Ethics statement
All mouse experiments were performed under research
protocols approved by the Duke University Animal Care and
Use Committee and were accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. All
procedures involving nonhuman primates were approved by the
Institutional Animal Care and Use Committee of Wake Forest
University, under accreditation by the Association for the
Assessment and Accreditation of Laboratory Animal Care.
Mice
BALB/c (H2
d) and C57BL/6 (H2
b) were purchased from The
Jackson Laboratories (Bar Harbor, Maine). Eight to twelve weeks
old female mice were used in this study, unless specifically noted.
Themicewere housedinaspecificpathogenfree facilitythroughout
the study. The mice were provided with autoclaved food and
acidified water. In our animal facility, sentinel mice were used to
ensure that the facility is clean. Serum samples from sentinel mice
were sent to the Research Animal Diagnostic Laboratory at
University of Missouri (Columbia, MO) once a quarter to test for
the following organisms: cilia associated respiratory bacillus,
ectromelia, encephalitozoon cuniculi, epizootic diarrhea of infant
mice virus, theiler’s murine encephalomyelitis virus, hantaan virus,
mouse pneumonitis virus, lymphocytic choriomeningitis virus,
mouse adenovirus-rodent adenovirus strain 1 (FL), mouse adeno-
virus-rodent adenovirus strain 2 (K87), mouse cytomegalovirus,
mouse hepatitis virus, minute virus of mice, murine norovirus,
mycoplasma pulmonis, mouse parvovirus, mouse thymic virus,
conserved, recombinant parvoviral protein (rNS1), polyoma virus,
pneumonia virus of mice, reovirus type 3, and sendai virus. During
the period of our study, all the results were negative.
rhGH. rhGH was made by Genentech (South San Francisco,
CA). For the in vivo studies, rhGH was reconstituted in saline and
stored at 4uC until use according to the manufacturer’s
instructions. rhGH was injected into mice intravenously via tail
vein at a dose of 20 mg/dose/day daily for 5 or 35 days post
irradiation. This dose was demonstrated to be safe, not to
significantly increase body weight, and effective in a hematopoietic
cell transplantation model [12]. For the in vitro studies, rhGH was
diluted in tissue culture media.
Irradiation
The mice were whole-body irradiated in a
137Cs gamma
irradiator (J.L. Shepherd and Associates, Glendale, CA). The dose
rate was between 6.3 and 6.7 Gy/minute.
Peripheral blood cell counts
Platelets were counted manually on a hemocytometer after
being diluted in 1% ammonium oxalate solution. White blood cells
were counted by flow cytometer based on CD45 staining using
Flow-Count fluorospheres (Beckmen Coulter, Miami, FL). Pre-
liminary experiments indicated that the flow cytometer is suitable
for counting mouse white blood cells.
Flow cytometry
For the murine studies, fifty ml of heparinized peripheral blood
was stained with monoclonal antibodies for 15 minutes at room
temperature. Red cells in the stained whole blood samples were
then lysed by FACS lysing solution (Becton Dickinson, San Jose,
CA). Fifty ml of Flow-Count fluorospheres (Beckmen Coulter) was
added before flow cytometric analysis. The stained cells were
analyzed using a FACSCanto flow cytometer (BD) equipped with
FACSDiva software. The flow tubes were drained in order to
collect all events. The absolute counts were calculated using the
following formula: Absolute count (cells/ml blood)=(Total number
of cells counted/Total number of fluorospheres counted)6Flow-
Count fluorosphere concentration. The antibodies and fluorescent
probes used in this study included 7-aminoactinomycin D (7-
AAD), fluorescein isothiocyanate (FITC)-conjugated Annexin V
and anti-CD49b (DX5); phycoerythrin (PE)-conjugated anti-CD3
(145-2C11) and anti-Sca-1 (E13–161.7); PE- cyanine (Cy)7-
conjugated anti-B220 (5326.7); allophycocyanin (APC)-conjugat-
ed anti-c-Kit (2B8); APC-Cy7-conjugated anti-CD45 (30F11) and
their isotype controls from BD; Tri-color-conjugated anti-B220
(RA3-6B2) and APC-conjugated anti-CD4 (RM4-5) and their
isotype controls from Caltag (South San Francisco, CA).
Colony forming unit assay
Bone marrow cells were flushed out from femurs and strained
through 70 mm strainers (Becton Dickinson, Franklin Lakes, NJ).
Colony forming units was measured using Methocult GF M3434
media (Stem Cell Technologies, Vancouver, Canada) in 35 mm
gridded dishes assayed at day 12–14. In some of the experiments,
cultures were resuspended in 15 ml of RPMI medium to dissolve
the methylcellulose following colony identification and enumera-
tion. After washing, cell counts and viability test were performed to
estimate the number of cells per colony.
Histology
Biopsies were taken from tibia and stored in buffered formalin.
Specimens were then embedded in paraffin, cut into 5 mm section,
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studied under light microscope. Images were acquired with an
AxioCam MRc digital camera mounted on an Axiovert 200
inverted microscope (Carl Zeiss Microimaging, Thornwood, NY).
A-Plan 10x/0.25 and LD-Plan NEOFLUAR 20X/0.4 and 40X/
0.6 objectives were used. Images were recorded using AxioVision
Rel. 4.5 software (Carl Zeiss Microimaging). The original,
unmodified pictures were used in this paper.
Isolation of hematopoietic stem cells
This procedure has been described previously with minor
modifications [13]. Whole bone marrow was collected from
bilateral femurs and tibias of 8–10 week old animals by flushing
with cold Dulbecco’s phosphate buffered saline (Invitrogen,
Carlsbad, CA), containing 10% heat-inactivated fetal bovine
serum (Hyclone, Logan, UT) and 100 U/ml penicillin and
100 ug/ml streptomycin (Invitrogen). Bone marrow mononuclear
cells were then isolated via density centrifugation, washed twice.
Lineage-marker negative (Lin
2) cells were then enriched via
magnetic column purification using the mouse lineage cell
depletion kit (Miltenyi Biotec, Auburn, CA), containing antibodies
to CD5, B220, CD11b, Ly-6G/C, 4–4, and Ter-119, according to
the manufacturer’s recommended protocol. Multiparameter flow
cytometry was conducted to isolate purified HSC subsets. Lin
2
cells were stained with FITC-conjugated anti-Sca-1, PE-conjugat-
ed anti-c-Kit antibodies (BD), or the appropriate isotype controls.
c-kit
+sca-1
+lin
2 (KSL) cells were sorted in a BD FACSVantage SE
flow cytometer, using FACSDiva software (Becton Dickinson).
Dead cells stained with 7-AAD were excluded from analysis and
sorting.
Osteoblast cell line
MC3T3E1 clone 4 cells (ATCC, Manassas, VA) were plated at
a density of 7,000 cells per well in 24-well plates in alpha-
MEM+10%Fetal Bovine Serum. Ascorbic acid was added to these
cultures at a concentration of 50 mg/ml. The cells grew in ascorbic
acid for a week, at which point the cells were washed with 16PBS
and resuspended in alphaMEM+10%FBS to prepare for co-
cultures.
In vitro culture of bone marrow stem cells
Once sorted, the murine bone marrow KSL cells were
irradiated in vitro using a Cs-137 irradiator. The irradiated KSL
cells were then seeded at 3,770 per well in 24-well plates (Becton
Dickinson) containing 1 ml/well culture medium (IMDM with
10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT)
and 100 U/ml penicillin and 100 ug/ml streptomycin (Invitro-
gen), 20 ng/ml stem cell factor (SCF), 50 ng/ml mouse fms-like
tyrosine kinase-3 (Flt-3) ligand, and 20 ng/ml mouse thrombo-
poietin (TSF; R&D Systems, Minneapolis, MN) with or without
7,000 osteoblastic MC3T3E1 clone 4 cells and non-contact
conditions using 0.4 um transwell inserts (Corning, Lowell MA).
The concentration of rhGH added to the culture was 5 nM. This
concentration was chosen based on the published data [7,8,9] and
our own preliminary experiments. Cells were cultured at 37uC,
5% CO2, 100% humidity and harvested after 7 days in culture to
measure colony forming cells (CFC) and colony forming units-
spleen (CFU-S). For the CFU-S assay, cells were quantified by
manual hemacytometer and 20,000 live cells were injected
intravenously into 9.5 Gy lethally irradiated C57BL/6 mice (5
per condition). Spleens were collected on day 11 and colonies were
visualized after organ fixation using Bouin’s fixative solution
(RICCA Chemical Company).
Mouse IGF-1 level
Mouse IGF-1 level was determined by enzyme-link immuno-
sorbent assay (ELISA) using a kit purchased from Signosis
(Sunnyvale, CA). Test samples and controls were added to
microtiter wells coated with goat anti-mouse IGF-1 antibody. After
incubation and washes, biotin labeled goat anti mouse IGF-1
antibody was added to the wells. Test samples and controls react
simultaneously with the two antibodies, resulting in the IGF-1
molecules being sandwiched between the solid phase and enzyme-
linked antibodies. After incubation, unbound antibodies are
removed. Streptavidin conjugated to horseradish peroxidase
(HRP) followed by HRP substrate are added for detection. The
concentration of IGF-1 is directly proportional to the color
intensity of the test sample. Absorbance is measured spectropho-
tometrically at 450 nm using a MRX microplate reader (Dynex
Technologies, Chantilly, VA).
Nonhuman primate studies
Adult male cynomolgus macaques (Macaca fascicularis) were
purchased from the Institut Pertanian Bogor (Bogor, Indonesia),
and housed socially in indoor pens at the Wake Forest University
Primate Center. All animals were determined to be in good health
by physical examination, and determined to be free of antibodies
to simian retroviruses. Irradiations were performed using a Varian
2100 EX dual energy linear accelerator. The single fraction whole
body dose of 2 Gy was given using 6 MV x rays at a dose rate of
0.69 Gy/min, using a pair of left and right lateral fields at
extended distance to deliver one-half the dose (1 Gy per field) to
each animal’s sagittal midline. Once established, animal position
was maintained for each lateral field. Anatomic measurements,
phantom studies and ionization chamber measurements were used
to establish the irradiation geometry and dose delivery parameters.
Clinical evaluations of macaques were done twice daily using a
modification of the Children’s Clinical Oncology Group toxicity
criteria to assess animals for signs of illness [55]. Starting on the
day of irradiation, treated animals were given a once daily
subcutaneous injection of rhGH (5 ug/kg/day), into the flank;
control animals were given an injection of 0.9% saline solution.
This continued for 30 days after irradiation. Blood counts
(hematocrit, red blood cells, red blood cell indices, total and
differential leukocyte counts, hemoglobin, and platelets), serum
chemistry panels (blood urea nitrogen, creatinine, total protein,
albumin, bilirubin, alanine aminotransferase, aspartate amino-
transferase, gamma-glutamyltransferase, potassium, sodium, chlo-
ride, and total CO2) were assayed daily (Antech Diagnostics) for
the first 5 days, then 3 times weekly for the remainder of a 30-day
period. Animals were sedated with ketamine for blood collection.
All animals were given parenteral prophylactic antibiotic treat-
ment, consisting of enrofloxacin (5 mg/kg) continuing until the
white blood cell count returned to the normal range. Supportive
fluid therapy, analgesics (ketoprofen), and symptomatic care were
given as needed, based on clinical pathology abnormalities and
clinical signs.
Statistical analysis
Observed measurements were summarized as mean6SD.
Comparison of cell counts, frequency of stem/progenitor cells,
CFU-S, and CFCs between groups was performed by Student’s t-
test (two groups) or analysis of variance (ANOVA) (.two groups).
When a difference was detected by ANOVA among the groups,
Fisher’s protected least significant difference test was used to
determine the significance of pairwise differences. The cell count
data shown in Fig. 2 & 3 were further analyzed by repeated
measures ANOVA. Survival data were analyzed by log rank test.
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StatView software (SAS institute, Cary, NC) or Microsoft Excel
(Microsoft, Seattle, WA). P values less than 0.05 were considered
significant.
The time-course profiles for the cell count data from the
nonhuman primate studies were estimated within the framework
of two-way multiplicative linear mixed effects analysis of co-
variance model [56]. The co-variables in the model were
treatment (saline vs. rhGH) and time. The latter was added based
on a natural spline basis [57] with knots at times 0, 16, 23, 31, and
60 days. A random effect term was used to account for inter-
subject variability. An auto-correlation dependence structure of
order 1 was assumed among the measurement errors for each
subject. These analyses were carried out using the R [58]
extension packages nlme and spline. An outlier in the rhGH-
treated group was excluded from the statistical analyses.
Supporting Information
Figure S1 rhGH-mediated mitigation against lethal irradiation
is not restricted to BALB/c mice. C57BL/6 mice were irradiated
with 9 Gy and treated with rhGH i.v. daily at a dose of 20 mg/
dose/day for 5 days. rhGH was given within one hour post
irradiation. The bars represent the period of the time that the
animals were treated. rhGH stands for recombinant human
growth hormone.
Found at: doi:10.1371/journal.pone.0011056.s001 (0.08 MB TIF)
Table S1 Effect of rhGH on blood citruline level. BALB/c mice
were irradiated with 7.5 Gy and treated with rhGH a for 5 days.
Plasma was harvested at day 3 and day 14 post irradiation. The
concentration of citruline was determined by high-performance
liquid chromatography. The baseline level of citruline in normal
BALB/c mice was 61.865.7 mg/ml plasma. Each group contains
7 animals. This is a representative of two experiments. rhGH
stands for recombinant human growth hormone.
Found at: doi:10.1371/journal.pone.0011056.s002 (0.04 MB
DOC)
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